Ourui One Facial Bump Refining Essence

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the improvement of skin texture through gentle exfoliation. It is designed to aid in the smoothing of the skin, making it suitable for individuals seeking to enhance the overall appearance and feel of their skin.

Dosage and Administration

The essence should be applied daily after cleansing and toning the skin. For optimal results, it is recommended to use the product twice a day for a minimum duration of 4 weeks. A pea-sized amount of the essence should be dispensed onto the affected area, and the fingertips should be used to gently massage the product into the skin until it is fully absorbed. Continued use is advised until the appearance of skin papules is no longer observed.

Contraindications

Use is contraindicated in children under 2 years of age due to the potential for adverse effects. Additionally, application on open skin wounds is contraindicated to prevent complications associated with infection or irritation.

Warnings and Precautions

For external use only. Healthcare professionals should advise patients to discontinue use and seek medical attention if any rash or irritation develops. It is imperative to monitor for signs of irritation or rash during treatment, and if such symptoms occur, patients should be instructed to stop using the product and consult a healthcare provider.

In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

This product is contraindicated for use in children under 2 years of age and should not be applied to open skin wounds. Healthcare professionals must ensure that patients are aware of these restrictions to prevent potential adverse effects.

Side Effects

Patients using this product should be aware that it is intended for external use only. In the event of rash or irritation, it is advised to discontinue use immediately and consult a healthcare professional.

Clinical observations indicate that irritation or rash may occur in some individuals. If such reactions are experienced, patients are strongly encouraged to seek medical advice.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Ourui One Facial Bump Refining Essence (salicylic acid 0.25% facial bump refining essence). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 2 years of age should not be administered this medication due to safety concerns. The efficacy and safety of the drug have not been established in this age group, and caution is advised when considering treatment options for younger children.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

There is no specific information regarding the use of this medication during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients. The potential risks and benefits should be carefully evaluated, and alternative treatments may be considered in the context of the patient's clinical situation. Women of childbearing potential should be counseled on the importance of effective contraception during treatment.

Lactation

There is no information available regarding the use of this drug in lactating mothers or its effects on breastfed infants. Healthcare professionals should consider the absence of data when advising lactating patients.

Renal Impairment

Patients with renal impairment have no specific information regarding dosage adjustments, special monitoring, or safety considerations provided in the text. Therefore, healthcare professionals should exercise caution and consider individual patient factors when prescribing to this population. Regular assessment of renal function may be warranted to ensure safe and effective use of the medication in patients with reduced kidney function.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant regarding the potential for overdose with this medication. In cases where an overdose is suspected, immediate medical attention should be sought.

Healthcare providers are advised to monitor patients closely for any signs or symptoms that may indicate an overdose. These may include, but are not limited to, increased severity of known side effects, unusual behavioral changes, or any other atypical clinical manifestations.

Management of an overdose should be guided by the clinical presentation of the patient. Supportive care is paramount, and symptomatic treatment should be initiated as necessary. It is recommended that healthcare professionals consult local poison control centers or relevant toxicology resources for specific guidance on the management of overdose cases.

In summary, while specific overdosage information is not available, healthcare professionals should exercise caution, remain observant for potential overdose symptoms, and implement appropriate management strategies as needed.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's safety profile in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact the Poison Control Center if the product is swallowed.

It is important to inform patients that the product should not be used in children under 2 years of age or on open skin wounds. Patients should be instructed to discontinue use and consult a doctor if they experience any irritation or rash.

Providers should emphasize the necessity of keeping the product away from the eyes, ears, mouth, and any open or broken skin areas. In the event of contact with the eyes, patients should be directed to rinse their eyes thoroughly with water.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product in a cool, shady place to maintain its integrity and efficacy. Proper storage conditions are crucial to ensure the product remains effective throughout its shelf life.

Additional Clinical Information

The product is administered topically, with a recommended application of once daily after cleansing and toning, or twice a day for a minimum of four weeks. Clinicians should counsel patients that the product is for external use only. Patients are advised to discontinue use and consult a doctor if a rash or irritation occurs. In case of contact with eyes, thorough rinsing with water is necessary. The product should be kept out of reach of children, and if ingested, medical assistance or contact with the Poison Control Center is required.

No additional information is available regarding laboratory tests, abuse potential, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Ourui One Facial Bump Refining Essence, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)